Advanced in Rabson-Mendenhall Syndrome

Dr. Anna Chang

Endocrinology
John Muir Physician Network
2700 Grant St Ste 200, 
Concord, CA 
Offers Telehealth
Advanced in Rabson-Mendenhall Syndrome
John Muir Physician Network
2700 Grant St Ste 200, 
Concord, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Chang is an Endocrinologist in Concord, California. Dr. Chang is rated as an Advanced provider by MediFind in the treatment of Rabson-Mendenhall Syndrome. Her top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and Gestational Diabetes.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in CA
Hospital Affiliations
John Muir Medical Center - Walnut Creek Campus
John Muir Medical Center - Concord Campus
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

John Muir Physician Network
2700 Grant St Ste 200, Concord, CA 94520
Call: 925-677-0515

Additional Areas of Focus

Dr. Chang has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Glargine
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
The Glooko Diabetes Mobile Monitoring and Management Advantage Study
The Glooko Diabetes Mobile Monitoring and Management Advantage Study
Enrollment Status: Completed
Publish Date: June 03, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.
Journal: Diabetes technology & therapeutics
Published: September 13, 2021
View All 8 Publications
Similar Doctors
Distinguished in Rabson-Mendenhall Syndrome
Dr. Marilyn Tan
Endocrinology
Distinguished in Rabson-Mendenhall Syndrome
Dr. Marilyn Tan
Endocrinology

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (38.2 miles away)
650-723-4000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marilyn Tan is an Endocrinologist in Palo Alto, California. Dr. Tan has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Rabson-Mendenhall Syndrome. Her top areas of expertise are Rabson-Mendenhall Syndrome, Low Blood Sugar, Type 2 Diabetes (T2D), and Diabetic Hyperglycemic Hyperosmolar Syndrome.

Distinguished in Rabson-Mendenhall Syndrome
Dr. Marina Basina
Endocrinology
Distinguished in Rabson-Mendenhall Syndrome
Dr. Marina Basina
Endocrinology

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (38.9 miles away)
650-723-6961
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Basina is an Endocrinologist in Stanford, California. Dr. Basina is rated as a Distinguished provider by MediFind in the treatment of Rabson-Mendenhall Syndrome. Her top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Papillary Thyroid Cancer, and Hyperthyroidism.

Advanced in Rabson-Mendenhall Syndrome
Dr. Umesh Masharani
Endocrinology
Advanced in Rabson-Mendenhall Syndrome
Dr. Umesh Masharani
Endocrinology

Center For Neuroendocrine Tumors

1825 4th St, 
San Francisco, CA 
 (24.5 miles away)
415-476-2212
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Umesh Masharani is an Endocrinologist in San Francisco, California. Dr. Masharani is rated as a Distinguished provider by MediFind in the treatment of Rabson-Mendenhall Syndrome. His top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Anaplastic Thyroid Cancer, Thyroid Cancer, and Islet Cell Transplantation.

VIEW MORE RABSON-MENDENHALL SYNDROME DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chang's expertise for a condition
ConditionClose
    • Distinguished
    • Maturity Onset Diabetes of the Young
      Dr. Chang is
      Distinguished
      . Learn about Maturity Onset Diabetes of the Young.
      See more Maturity Onset Diabetes of the Young experts
    • Type 1 Diabetes (T1D)
      Dr. Chang is
      Distinguished
      . Learn about Type 1 Diabetes (T1D).
      See more Type 1 Diabetes (T1D) experts
    • Type 2 Diabetes (T2D)
      Dr. Chang is
      Distinguished
      . Learn about Type 2 Diabetes (T2D).
      See more Type 2 Diabetes (T2D) experts
    • Advanced
    • Anaplastic Thyroid Cancer
      Dr. Chang is
      Advanced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Diabetic Hyperglycemic Hyperosmolar Syndrome
      Dr. Chang is
      Advanced
      . Learn about Diabetic Hyperglycemic Hyperosmolar Syndrome.
      See more Diabetic Hyperglycemic Hyperosmolar Syndrome experts
    • Diabetic Nephropathy
      Dr. Chang is
      Advanced
      . Learn about Diabetic Nephropathy.
      See more Diabetic Nephropathy experts
    • Diabetic Neuropathy
      Dr. Chang is
      Advanced
      . Learn about Diabetic Neuropathy.
      See more Diabetic Neuropathy experts
    • Follicular Thyroid Cancer
      Dr. Chang is
      Advanced
      . Learn about Follicular Thyroid Cancer.
      See more Follicular Thyroid Cancer experts
    • Gestational Diabetes
      Dr. Chang is
      Advanced
      . Learn about Gestational Diabetes.
      See more Gestational Diabetes experts
    View All 23 Advanced Conditions
    • Experienced
    • Addison's Disease
      Dr. Chang is
      Experienced
      . Learn about Addison's Disease.
      See more Addison's Disease experts
    • Albright's Hereditary Osteodystrophy
      Dr. Chang is
      Experienced
      . Learn about Albright's Hereditary Osteodystrophy.
      See more Albright's Hereditary Osteodystrophy experts
    • Alopecia Areata
      Dr. Chang is
      Experienced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Autosomal Dominant Hypocalcemia
      Dr. Chang is
      Experienced
      . Learn about Autosomal Dominant Hypocalcemia.
      See more Autosomal Dominant Hypocalcemia experts
    • Autosomal Recessive Hypotrichosis
      Dr. Chang is
      Experienced
      . Learn about Autosomal Recessive Hypotrichosis.
      See more Autosomal Recessive Hypotrichosis experts
    • Diabetes Insipidus (DI)
      Dr. Chang is
      Experienced
      . Learn about Diabetes Insipidus (DI).
      See more Diabetes Insipidus (DI) experts
    View All 57 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.